Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001171843-23-002053
Filing Date
2023-04-03
Accepted
2023-04-03 06:05:09
Documents
12
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K f6k_040323.htm 6-K 9072
2 EXHIBIT 99.1 exh_991.htm EX-99.1 567924
3 EXHIBIT 99.2 exh_992.htm EX-99.2 316004
4 EXHIBIT 99.3 exh_993.htm EX-99.3 670872
5 EXHIBIT 99.4 exh_994.htm EX-99.4 6892
6 EXHIBIT 99.5 exh_995.htm EX-99.5 6934
7 GRAPHIC logo.jpg GRAPHIC 16874
8 GRAPHIC logo_footer.jpg GRAPHIC 6975
9 GRAPHIC org_chart.jpg GRAPHIC 11261
10 GRAPHIC smythe.jpg GRAPHIC 3494
11 GRAPHIC smythe2.jpg GRAPHIC 10253
12 GRAPHIC smythe3.jpg GRAPHIC 1618
  Complete submission text file 0001171843-23-002053.txt   1649009
Mailing Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5
Business Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5 403-607-2621
XORTX Therapeutics Inc. (Filer) CIK: 0001729214 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40858 | Film No.: 23790288
SIC: 2834 Pharmaceutical Preparations